PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours

PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours

Item
http://www.wikidata.org/entity/Q33404024
Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugsProgress toward overcoming hypoxia-induced resistance to solid tumor therapyDefining normoxia, physoxia and hypoxia in tumours-implications for treatment responseSulforaphane Preconditioning Sensitizes Human Colon Cancer Cells towards the Bioreductive Anticancer Prodrug PR-104AThe hypoxia-activated prodrug evofosfamide in combination with multiple regimens of radiotherapy.GdDO3NI, a nitroimidazole-based T1 MRI contrast agent for imaging tumor hypoxia in vivo.F-18 fluoromisonidazole for imaging tumor hypoxia: imaging the microenvironment for personalized cancer therapyThe Role of Bystander Effects in the Antitumor Activity of the Hypoxia-Activated Prodrug PR-104.Zinc finger nuclease knock-out of NADPH:cytochrome P450 oxidoreductase (POR) in human tumor cell lines demonstrates that hypoxia-activated prodrugs differ in POR dependence.Design of optimized hypoxia-activated prodrugs using pharmacokinetic/pharmacodynamic modeling.Molecular imaging of tumor hypoxia with positron emission tomography.Hypoxia-activated prodrugs: paths forward in the era of personalised medicine.Quantification of Tumor Hypoxic Fractions Using Positron Emission Tomography with [18F]Fluoromisonidazole ([18F]FMISO) Kinetic Analysis and Invasive Oxygen Measurements.Synthesis and Biological Evaluation of Benzocyclooctene-based and Indene-based Anticancer Agents that Function as Inhibitors of Tubulin Polymerization.Targeting Hypoxia to Improve Non-Small Cell Lung Cancer Outcome.Bystander Effects of Hypoxia-Activated Prodrugs: Agent-Based Modeling Using Three Dimensional Cell Cultures
P2860

PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours

Item
http://www.wikidata.org/entity/Q33404024
description
2012 nî lūn-bûn
@nan
2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
PR-104 a bioreductive pre-prod ...... ts with advanced solid tumours
@ast
PR-104 a bioreductive pre-prod ...... ts with advanced solid tumours
@en
type
label
PR-104 a bioreductive pre-prod ...... ts with advanced solid tumours
@ast
PR-104 a bioreductive pre-prod ...... ts with advanced solid tumours
@en
prefLabel
PR-104 a bioreductive pre-prod ...... ts with advanced solid tumours
@ast
PR-104 a bioreductive pre-prod ...... ts with advanced solid tumours
@en
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P407
P478
P50
P577
P5875
P6179
P698
P932
P356
P1433
P1476
PR-104 a bioreductive pre-prod ...... ts with advanced solid tumours
@en
P2093
P2860
P2888
P304
P31
P356
P407
P478
P50
P577
P5875
P6179
P698
P932